5-Amino-1MQ vs Livagen
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
5-Amino-1MQAnti-Aging & Longevity
Livagen- Summary
- 5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
- Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
- Half-Life
- Estimated 4–8 hours
- Short (minutes); gene-regulatory effects are sustained
- Admin Route
- Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 50–100 mg
- 10 mg per day
- Frequency
- Once to twice daily
- Daily for 10–30 days
- Key Benefits
- Raises intracellular NAD+ levels
- Directly targets adipose tissue for fat reduction
- Reduces fat cell size and differentiation
- Increases basal metabolic rate
- SIRT1 activation for metabolic regulation
- No stimulant cardiovascular side effects
- Synergistic with intermittent fasting and caloric restriction
- May have anti-aging metabolic benefits
- Supports hepatocyte regeneration and liver tissue repair
- Normalizes liver cell protein synthesis
- Immune modulation via thymic activity
- Potential benefits in chronic hepatitis and liver aging
- Anti-aging effects on hepatic tissue
- May support liver recovery after toxic insult or alcohol damage
- Complementary to NAD+ and glutathione in liver health protocols
- Side Effects
- Generally well-tolerated in available studies
- Mild GI discomfort (rare)
- Limited long-term human data
- Generally well tolerated
- Mild injection site reactions
- No significant hepatotoxic effects reported at standard doses
- Stacks With
- —
- —